SCHEMBL4757490

SCHEMBL4757490

NCc1ccc(-c2nc3c(N4CCN(Cc5cncc(F)c5)CC4)c(Cl)cnc3[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AURKA O14965 12/20 0.50
DRD2 P14416 5/20 0.40
DRD4 P21917 5/20 0.40
DRD3 P35462 5/20 0.40
GNRHR P30968 1/20 0.39
PARP1 P09874 1/20 0.39
DHODH Q02127 1/20 0.39
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13985464 0.90 AURKA (0.50) AURKADRD2DRD4DRD3GNRHR
SCHEMBL13985474 0.86 AURKA (0.52) AURKADRD2DRD4DRD3GNRHR
SCHEMBL13985732 0.83 AURKA (0.48) AURKAGNRHRPARP1KCNH2
SCHEMBL4754714 0.82 AURKA (0.52) AURKADRD2DRD4DRD3KCNH2
SCHEMBL13985467 0.82 AURKA (0.34) AURKADRD2DRD4DRD3GNRHR
SCHEMBL4756403 0.80 AURKA (0.76) AURKAKCNH2
SCHEMBL210868 0.79 AURKA (0.50) AURKAKCNH2
SCHEMBL4757483 0.78 AURKA (0.59) AURKAKCNH2
SCHEMBL13985465 0.77 AURKA (0.51) AURKADRD2DRD4DRD3KCNH2
SCHEMBL14495854 0.77 AURKA (0.50) AURKADRD2DRD4DRD3GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001021-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES CHROMA THERAPEUTICS LTD. (GB) 2008-12-31 WO claimed
WO-2009001021-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES CHROMA THERAPEUTICS LTD. (GB) 2008-12-31 WO disclosed